Aleksandra Mospinek

Ms. Aleksandra Mospinek

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2025 in Biology
Verified
Journal Article
Open access
PDF file
GMGrzegorz Mrugacz
Grzegorz Mrugacz
AMAleksandra Mospinek
Aleksandra Mospinek
MJMałgorzata Jagielska
Małgorzata Jagielska
DMDariusz Miszczak
Dariusz Miszczak
AMAnna Matosek
Anna Matosek
SPSvetlana Pekar
Svetlana Pekar
Background: Artificial Intelligence (AI) has emerged as a transformative tool in in vitro fertilization (IVF) as it has done in other sectors. In IVF, AI offers advancements in embryo selection, treatment personalization, and outcome prediction. It does so by leveraging deep learning and computer vision, as well as AI-driven platforms such as ERICA, iDAScore, and IVY where the goal is to address the limitations of traditional embryo assessment. Key amongst them are the issues of subjectivity, labor intensity, and limited predictive power. Despite rapid technological progress, the integration of AI into routine IVF practice faces key challenges. These are issues related to clinical validation, ethical dilemmas, and workflow adaptation. Rationale/Objectives: This review synthesizes current evidence to evaluate the role of AI in IVF, focusing on six critical dimensions: (1) the evolution of AI from traditional embryology to algorithmic assessment, (2) clinical validation and regulatory considerations, (3) limitations and ethical challenges, (4) pathways for clinical integration, (5) real-world applications and outcomes, and (6) future directions and policy recommendations. The objective is to provide a comprehensive roadmap for the responsible adoption of AI in reproductive medicine. Outcomes: AI demonstrates significant potential to improve the precision and efficiency of IVF. Studies report that AI models can achieve 10 to 25% higher accuracy in predicting embryo viability and implantation potential compared to traditional morphological assessment by embryologists. This enhanced predictive power supports more consistent embryo ranking, facilitates elective single-embryo transfer (eSET) strategies, and is associated with 30 to 50% reductions in embryologist workload per embryo cohort. Early adopters report promising trends. However, large-scale randomized controlled trials have yet to conclusively demonstrate a statistically significant increase in live birth rates per transfer compared to expert embryologist selection. The most immediate and evidenced value of AI lies in hybrid decision-making models. This is where it augments embryologists by providing data-driven, objective support, thereby standardizing workflows and reducing subjectivity. Wider Implications: The sustainable integration of AI into IVF banks on three key aspects: robust evidence generation, interdisciplinary collaboration, and global standardization. To foster these, policymakers ought to establish regulatory frameworks for transparency and bias mitigation. On their part, clinicians need training to interpret AI outputs critically. Ethically, safeguarding patient trust and equity is non-negotiable. Future innovations, mainly AI-enhanced genomics and real-time monitoring, could further personalize care. However, their success depends on addressing current limitations. By balancing innovation with ethical vigilance, AI holds the potential to revolutionize IVF while upholding the highest standards of patient care.

14 October 2025 in Cells
Verified
Journal Article
Open access
PDF file
GMGrzegorz Mrugacz
Grzegorz Mrugacz
AMAleksandra Mospinek
Aleksandra Mospinek
JGJoanna Głowacka
Joanna Głowacka
OSOskar Sprawski
Oskar Sprawski
LKLidia Kawałek
Lidia Kawałek
WSWeronika Małgorzata Szczepańska
Weronika Małgorzata Szczepańska
Background: Recurrent pregnancy loss (RPL) and recurrent implantation failure (RIF) are significant challenges in reproductive medicine. For both, embryonic aneuploidy is the leading etiological factor. Preimplantation genetic testing for aneuploidy (PGT-A) via trophectoderm biopsy is the current standard for embryo selection. However, it is limited by its invasiveness, potential for embryo damage, and diagnostic errors due to mosaicism. Rationale/Objectives: This review critically evaluates the emerging role of noninvasive PGT (niPGT). NiPGT analyzes cell-free DNA from spent blastocyst culture media, thus, it is a potential alternative for managing RPL and RIF. Hence, the primary objective is to determine whether current evidence supports niPGT as a reliable replacement for conventional biopsy-based PGT-A in these high-risk populations. Outcomes: The analysis reveals that niPGT offers significant theoretical advantages. These include complete non-invasiveness, enhanced embryo preservation, and high patient acceptability. However, its clinical application is hampered by substantial limitations. Key amongst them is the inconsistent and often suboptimal diagnostic accuracy (sensitivity 70–85%, specificity 88–92%) compared to biopsy. Other significant factors include the high rates of amplification failure (10–50%), vulnerability to maternal DNA contamination, as well as low DNA yield. Crucially, there is a definitive lack of robust, prospective randomized controlled trial (RCT) data demonstrating improved live birth rates or reduced miscarriage rates specifically in RPL and RIF cohorts. As such, niPGT is not yet ready to be a standalone clinical adoption in RPL and RIF cases. However, it may serve as a valuable adjunct for rescue scenarios following biopsy failure or for ethical reasons. Wider Implications: The integration of niPGT with artificial intelligence, time-lapse imaging, and multi-omics profiling underlies a promising future. However, its transition from a predominantly research tool to a clinical standard necessitates various critical undertakings. These include rigorous multicenter RCTs, standardizing international protocol, and tailoring validation for the RPL and RIF subgroups. This review highlights the need for cautious optimism, positing that evidence-based integration, rather than premature adoption, is essential to realizing niPGT’s full potential without compromising patient care in these complex fertility scenarios.

29 July 2025 in Biology
Verified
Journal Article
Open access
PDF file
GMGrzegorz Mrugacz
Grzegorz Mrugacz
AMAleksandra Mospinek
Aleksandra Mospinek
MMMaria Modrzyńska-Olejniczak
Maria Modrzyńska-Olejniczak
BBBartłomiej Byczkowski
Bartłomiej Byczkowski
EREwelina Radaj
Ewelina Radaj
Piotr OlchaPiotr Olcha
Piotr Olcha
Endometriosis significantly impacts fertility through complex mechanisms. These include chronic inflammation, oxidative stress, and anatomical distortion. These mechanisms impair oocyte quality, embryo development, and implantation. While in vivo challenges persist, in vitro fertilization (IVF) offers a controlled environment to overcome some barriers. A systematic review of evidence is presented for (1) endometriosis-associated oocyte dysfunction, (2) conflicting IVF outcomes, and (3) innovative strategies. Significant medical advancements have been made. However, gaps remain in personalized prognosis and targeted therapies. Emerging tools, specifically AI-driven embryo selection, single-cell omics, and immunomodulation, are promising for improving outcomes. Hence, a patient-centered approach, balancing science with personalized care, is essential to navigate endometriosis-related infertility.

10 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
GMGrzegorz Mrugacz
Grzegorz Mrugacz
AMAleksandra Mospinek
Aleksandra Mospinek
JGJoanna Głowacka
Joanna Głowacka
OSOskar Sprawski
Oskar Sprawski
LKLidia Kawałek
Lidia Kawałek
WSWeronika Małgorzata Szczepańska
Weronika Małgorzata Szczepańska

Background: Recurrent pregnancy loss (RPL) and recurrent implantation failure (RIF) are significant challenges in reproductive medicine. For both, embryonic aneuploidy is the leading etiological factor. Preimplantation genetic testing for aneuploidy (PGT-A) via trophectoderm biopsy is the current standard for embryo selection. However, it is limited by its invasiveness, potential for embryo damage, and diagnostic errors due to mosaicism. Rationale/Objectives: This review critically evaluates the emerging role of noninvasive PGT (niPGT). NiPGT analyzes cell-free DNA from spent blastocyst culture media, thus is a potential alternative for managing RPL and RIF. Hence, the primary objective is to determine whether current evidence supports niPGT as a reliable replacement for conventional biopsy-based PGT-A in these high-risk populations. Outcomes: The analysis reveals that niPGT offers significant theoretical advantages. These include complete non-invasiveness, enhanced embryo preservation, and high patient acceptability. However, its clinical application is hampered by substantial limitations. Key amongst them is the inconsistent and often suboptimal diagnostic accuracy (sensitivity 70-85%, specificity 88-92%) compared to biopsy. Other significant factors include the high rates of amplification failure (10-50%), vulnerability to maternal DNA contamination, as well as low DNA yield. Crucially, there is a definitive lack of robust, prospective randomized controlled trial (RCT) data demonstrating improved live birth rates or reduced miscarriage rates specifically in RPL and RIF cohorts. As, niPGT is not yet ready to be a standalone clinical adoption in RPL and RIF cases. However, it may serve as a valuable adjunct for rescue scenarios following biopsy failure or for ethical reasons. Wider Implications: The integration of niPGT with artificial intelligence, time-lapse imaging, and multi-omics profiling underlies a promising future. However, its transition from a predominantly research tool to a clinical standard necessitates various critical undertakings. These include rigorous multicenter RCTs, standardizing international protocol, and tailoring validation for the RPL and RIF subgroups. This review highlights the need for cautious optimism, positing that evidence-based integration, rather than premature adoption, is essential to realizing niPGT’s full potential without compromising patient care in these complex fertility scenarios.